Target detail
ACSL5
acyl-CoA synthetase long chain family member 5
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: acyl-CoA synthetase long chain family member 5
Aliases: ACSL5, acyl-CoA synthetase long chain family member 5
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000197142
Index freshness: last_synced_at 2026-05-15T18:42:09.225+00:00 · updated 2026-05-15T18:42:09.704794+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ACSL5. Empty groups mean no matching rows — not a claim about biology or clinical use.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
- ChEMBLLive when indexed
Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).
- CANTI signal builderLive when indexed
Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
SORAFENIB
chembl1336
MOTESANIB
chembl572881
DEFOSBARASERTIB
chembl215152
CANERTINIB
chembl31965
CP-724714
chembl483321
BOSUTINIB
chembl288441
KW-2449
chembl1908397
AT-9283
chembl495727
XL-228
chembl3545085
BAFETINIB
chembl206834
SARACATINIB
chembl217092
EVEROLIMUS
chembl1908360
TEMSIROLIMUS
chembl1201182
NERATINIB
chembl180022
DACTOLISIB
chembl1879463
CHEMBL4778736
chembl4778736
CHEMBL4757253
chembl4757253
CHEMBL4751846
chembl4751846
CHEMBL4798042
chembl4798042
CHEMBL4761388
chembl4761388
CHEMBL222502
chembl222502
CHEMBL4749993
chembl4749993
CHEMBL4792940
chembl4792940
CHEMBL4789782
chembl4789782
CHEMBL4776019
chembl4776019
LY-2584702
chembl3545076
FASUDIL
chembl38380
PONATINIB
chembl1171837
BINIMETINIB
chembl3187723
SOTRASTAURIN
chembl565612
TEPOTINIB
chembl3402762
MILCICLIB
chembl564829
GOLVATINIB
chembl3039525
TAK-901
chembl3544932
REFAMETINIB
chembl1236682
MOMELOTINIB
chembl1078178
VOLASERTIB
chembl1233528
ENMD-2076
chembl482968
AEW-541
chembl551064
FOSTAMATINIB
chembl2103830
AZD-4547
chembl3184679
ICOTINIB
chembl2087361
CHEMBL3218575
chembl3218575
DACOMITINIB ANHYDROUS
chembl2110732
ENTRECTINIB
chembl1983268
COBIMETINIB
chembl2146883
PF-00477736
chembl3545137
XL-019
chembl3545328
SAVOLITINIB
chembl3334567
CAPIVASERTIB
chembl2325741
MK-8033
chembl2323775
OSI-027
chembl3120215
CHEMBL3991933
chembl3991933
CHEMBL3699142
chembl3699142
TIVANTINIB
chembl2103882
RAVOXERTINIB
chembl3544964
SGI-1776
chembl1952329
PIMASERTIB
chembl2107832
AZD-7762
chembl2041933
K-252A
chembl281948
CC-401
chembl1614713
SAR-407899 FREE BASE
chembl1667969
CHEMBL3991935
chembl3991935
TIRBANIBULIN
chembl571546
CRENOLANIB
chembl2105728
TAK-285
chembl1614725
NMS-1286937
chembl1094408
MK-2206
chembl1079175
AC-480
chembl1645462
TIVOZANIB
chembl1289494
TELATINIB
chembl2079588
DINACICLIB
chembl2103840
PH-797804
chembl1088751
RIDAFOROLIMUS
chembl2103839
PEXMETINIB
chembl3991932
REGORAFENIB
chembl1946170
VEMURAFENIB
chembl1229517
RAF-265
chembl558752
TOZASERTIB
chembl572878
LINIFANIB
chembl223360
TOFACITINIB
chembl221959
DASATINIB
chembl5416410
ERLOTINIB
chembl553
GEFITINIB
chembl939
PAZOPANIB
chembl477772
SELICICLIB
chembl14762
ALVOCIDIB
chembl428690
IMATINIB
chembl941
LAPATINIB
chembl554
TANDUTINIB
chembl124660
VATALANIB
chembl101253
SU-014813
chembl1721885
SUNITINIB
chembl535
VANDETANIB
chembl24828
SAPITINIB
chembl2408045
CHEMBL3991934
chembl3991934
PF-03814735
chembl4289017
OMIPALISIB
chembl1236962
TALMAPIMOD
chembl514201
BARICITINIB
chembl2105759
PERIFOSINE
chembl372764
BMS-690514
chembl3545396
AMUVATINIB
chembl2103851
RO-4987655
chembl1614766
CUDC-101
chembl598797
ULIXERTINIB
chembl3590106
RGB-286638
chembl3545083
VISTUSERTIB
chembl2336325
TG100-801
chembl403989
GLESATINIB
chembl3989914
DEFACTINIB
chembl3137331
AEE-788
chembl587723
IDELALISIB
chembl2216870
GILTERITINIB
chembl3301622
Y-39983
chembl571948
RIVOCERANIB
chembl3186534
JNJ-38877605
chembl2133806
CABOZANTINIB
chembl2105717
BMS-911543
chembl3545215
VARLITINIB
chembl2103842
AZD-6482
chembl2165191
BMS-777607
chembl460702
HYDROXYFASUDIL
chembl1233300
CRIZOTINIB
chembl601719
CHEMBL400402
chembl400402
NINTEDANIB
chembl502835
BI-2536
chembl513909
TG100-115
chembl230011
MASITINIB
chembl1908391
SCH-900776
chembl2386889
TAK-593
chembl2180604
AZD-8186
chembl3408248
TESEVATINIB
chembl3544983
GALUNISERTIB
chembl2364611
SNS-314
chembl482767
PF-04217903
chembl2001019
DECERNOTINIB
chembl3039513
ZOTIRACICLIB
chembl1944698
OSI-930
chembl1614710
LENVATINIB
chembl1289601
COPANLISIB
chembl3218576
GSK-2636771
chembl3188551
AZD-5438
chembl488436
AMG-208
chembl496102
RABUSERTIB
chembl3039517
CERITINIB
chembl2403108
PF-00562271
chembl1084546
ADAVOSERTIB
chembl1976040
LESTAURTINIB
chembl603469
CEDIRANIB
chembl491473
PF-03758309
chembl3128043
FGFR INHIBITOR DEBIO 1347
chembl3907479
ORANTINIB
chembl274654
TANZISERTIB
chembl1950289
VX-702
chembl1090090
PEXIDARTINIB
chembl3813873
BARASERTIB
chembl415049
GEDATOLISIB
chembl592445
AV-412 FREE BASE
chembl2138625
Cerdulatinib Hydrochloride
chembl3991929
OSI-632
chembl253969
WHI-P131
chembl405130
AXL-1717
chembl283120
JNJ-26483327
chembl3109738
CHEMBL3991931
chembl3991931
TIDEGLUSIB
chembl3545157
AT-13148
chembl3544960
UCN-01
chembl574737
LOSMAPIMOD
chembl1088752
SELUMETINIB
chembl1614701
R-406
chembl475251
GSK-461364
chembl1908394
BRIVANIB
chembl377300
AXITINIB
chembl1289926
SGX-523
chembl1236107
GSK-690693
chembl494089
BRIVANIB ALANINATE
chembl270995
PALBOCICLIB
chembl189963
ALISERTIB
chembl483158
AFATINIB
chembl1173655
FORETINIB
chembl1230609
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
No matching live evidence found
Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.
Repurposing signal rows for drugs linked to this target via drug_targets.
Repurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · AT-9283 · v0.1
Deterministic research signal for AT-9283. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BAFETINIB · v0.1
Deterministic research signal for BAFETINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubStructured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).
- chembl: 181
- canti_signal_builder: 5
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
Repurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · AT-9283 · v0.1
Deterministic research signal for AT-9283. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BAFETINIB · v0.1
Deterministic research signal for BAFETINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hub